FDA panel backs Vivitrol for opioid dependence

FDA's Psychopharmacologic Drugs Advisory Committee voted 12-1 to recommend approval of an sNDA from Alkermes

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE